Family · Pharmaceutical analytical standards
Regorafenib
An oral multikinase inhibitor that blocks several proteins involved in the growth of tumours and of the blood vessels that feed them; approved in 2012 for metastatic colorectal cancer, later also for GIST and liver cancer. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.
Did you know?It is almost identical to sorafenib, another cancer medicine: the only structural difference is one extra fluorine atom on the central ring of the molecule.
No product matches your search.
EDQM standards 5
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
